studiedDrug

47 triples

GPTKB property

testedDrug

Subject	Object
gptkb:CheckMate_227	gptkb:nivolumab
gptkb:RE-LY_trial	gptkb:warfarin
gptkb:PolyHeme_Phase_III_Clinical_Trial	gptkb:PolyHeme
gptkb:Adaptive_COVID-19_Treatment_Trial_1	placebo
gptkb:Rivaroxaban_Once_Daily_Oral_Direct_Factor_Xa_Inhibition_Compared_with_Vitamin_K_Antagonism_for_Prevention_of_Stroke_and_Embolism_Trial_in_Atrial_Fibrillation	gptkb:rivaroxaban
gptkb:Justification_for_the_Use_of_Statins_in_Prevention:_an_Intervention_Trial_Evaluating_Rosuvastatin	gptkb:rosuvastatin
gptkb:RE-LY_trial	gptkb:dabigatran
gptkb:DESCARTES_trial	gptkb:evolocumab
gptkb:CANTOS_trial	gptkb:canakinumab
gptkb:Solidarity_trial_(WHO)	gptkb:interferon_beta-1a
gptkb:JUPITER_trial	gptkb:rosuvastatin
gptkb:Solidarity_trial_(WHO)	gptkb:lopinavir/ritonavir
gptkb:ELIANA_trial	gptkb:tisagenlecleucel
gptkb:IMpower150	gptkb:bevacizumab
gptkb:FOURIER_trial	gptkb:evolocumab
gptkb:Solidarity_trial	gptkb:remdesivir
gptkb:COVID-19_Solidarity_Trial_(WHO)	gptkb:lopinavir/ritonavir
gptkb:ACTT-1	placebo
gptkb:JULIET_trial	gptkb:tisagenlecleucel
gptkb:KEYNOTE-024:_Pembrolizumab_versus_Chemotherapy_for_PD-L1–Positive_Non–Small-Cell_Lung_Cancer	gptkb:pembrolizumab